ClinicalTrials.gg

Epilepsy clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,848 studies for Epilepsy across more than 10 countries. 419 are recruiting or about to start. 1,259 of them are mainly about Epilepsy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 12 narrower conditions too, such as Drug Resistant Epilepsy: 2,335 studies, 550 open.

ClinicalTrials.gov finds 2,554 studies for Epilepsy. How that becomes 1,848 here

This page counts the studies the registry files under Epilepsy, and those it files under no condition that list Epilepsythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,554Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −487Filed under a narrower condition, counted on its own pageDrug Resistant Epilepsy 155 · Epilepsies, Partial 112 · Epilepsies, Myoclonic 58 · Spasms, Infantile 36 · Epilepsy, Temporal Lobe 29 · Lennox Gastaut Syndrome 20 · 6 more
  3. −48List Epilepsy as a condition, but the registry did not file them under itMost often written as “STXBP1 Encephalopathy With Epilepsy” (4), “Epilepsy in Children” (4), and “Photosensitive Epilepsy” (3). The registry filed them under other conditions only, most often Epilepsy, Post-Traumatic (5) and Epileptic Encephalopathy, Early Infantile, 4 (5).
  4. −171Match it another way61 name it in the title, 15 in a keyword, and 95 by a synonym or other text the search reads.
  5. 1,848The count on this page36 of them list Epilepsy in their own words; the registry filed them under no condition.

Status

Completed
988
Recruiting
284
Status unknown
170
Terminated
139
Not yet recruiting
83
Active, not recruiting
67

Phase

Phase 3
267
Phase 2
210
Phase 1
146
Phase 4
119
Early Phase 1
16

Where

United States
793
France
254
United Kingdom
151
Germany
138
Italy
128
Belgium
110

Who develops what

Add Epilepsy to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 12 programs from 10 companies, 7 with this as their studies’ main aim; 5 with a live phase 3 study; 6 primary completions in the next 12 months. Compare H. Lundbeck and Sino Biopharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TopiramateEarlier only
Evidence
  • NCT01229735 · UCB S.A. · Phase 4 · comparator · “Topiramate” · registered Oct 2010
  • NCT00563459 · SK Biopharmaceuticals · Phase 3 · comparator · “topiramate” · registered Nov 2007
  • NCT00154076 · Eisai Co., Ltd. · Phase 4 · comparator · “Topiramate” · registered Sep 2005
Johnson & Johnson68% of its industry studiesUS: off-patent, 29 generics marketed00 studies
LevetiracetamEarlier only
Evidence
  • NCT02201251 · Johnson & Johnson · Phase 3 · comparator · “Levetiracetam” · registered Jul 2014
  • NCT00563459 · SK Biopharmaceuticals · Phase 3 · comparator · “levetiracetam” · registered Nov 2007
UCB S.A.78% of its industry studiesUS: off-patent, 52 generics marketedEU: off-patent, 8 generics authorized00 studies
CarbamazepineEarlier only
Evidence
  • NCT01954121 · UCB S.A. · Phase 3 · comparator · “Carbamazepine” · registered Sep 2013
  • NCT01127256 · Eisai Co., Ltd. · Phase 4 · comparator · “carbamazepine” · registered May 2010
GRIN Therapeutics, Inc.10% of its industry studiesUS: off-patent, 26 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
relutrigine☆ Track1 live phase-3 study: NCT07010471Praxis Precision Medicines
elsunersen☆ Track1 live phase-3 study: NCT07019922Praxis Precision Medicines

The 2 in phase 3 with the nearest primary completion, of 12 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.relutrigine · Praxis Precision Medicines · Phase 3 main aimNCT07010471 A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine — primary endpoint: To assess the effect of relutrigine on seizure frequency in participants with DEEs compared to placebo · 160 enrolled
  • Dec 2026 est.elsunersen · Praxis Precision Medicines · Phase 3 main aimNCT07019922 A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety — primary endpoint: To assess the efficacy of elsunersen on seizure frequency in participants with early-onset SCN2A DEE · 40 enrolled
  • 31 Dec 2026 est.bexicaserin · H. Lundbeck A/S · Phase 3 named, not the main aimNCT06660394 A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) — primary endpoint: Frequency Percent Change in Countable Motor Seizures During Treatment Compared to Baseline · 108 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Epilepsy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here mTOR inhibitors 2 open · SSRIs 1 open · Serotonin receptor agonists 1 open · Calcium channel blockers 1 open · Anxiolytics 22

Coming up

145studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger. 139 (49%) take children under 18. 6 (2%) are for women only and 3 (1%) for men only; 55 (19%) take healthy volunteers.

Recruiting studies that take each age, of 284
AgeWomenMen
10102 (36%)102 (36%)
18246 (87%)241 (85%)
30226 (80%)223 (79%)
40223 (79%)221 (78%)
50217 (76%)215 (76%)
65190 (67%)188 (66%)
75152 (54%)150 (53%)
85130 (46%)128 (45%)

Across all 1,848 studies, recruiting or not: 55% stop at 75 or younger and 46% at 65; 49% take children; 2% are for women only and 1% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Epilepsy studies take

Of 85 phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 18 mo3–22 · 55 studies4 mo1–10 · 34 studies—
Phase 223 mo14–40 · 66 studies21 mo11–29 · 45 studies—
Phase 348 mo29–69 · 85 studies48 mo30–70 · 66 studies—
Phase 425 mo12–36 · 43 studies—26 mo11–37 · 33 studies
Interventional, no phase42 mo19–77 · 359 studies—42 mo19–77 · 338 studies
Observational59 mo24–109 · 231 studies34 mo17–59 · 38 studies62 mo33–179 · 193 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,848. Browse all 1,848 → or search them.